SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Authors
Keywords
-
Journal
LEUKEMIA
Volume 30, Issue 2, Pages 399-408
Publisher
Springer Nature
Online
2015-09-04
DOI
10.1038/leu.2015.240
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
- (2015) X. Leleu et al. BLOOD
- The development of potential antibody-based therapies for myeloma
- (2015) Daniel W. Sherbenou et al. BLOOD REVIEWS
- Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death
- (2014) Ana M. Villamil Giraldo et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Daratumumab granted breakthrough drug status
- (2014) Jacob P Laubach et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma
- (2014) Jesus Berdeja Frontiers in Bioscience-Landmark
- Elotuzumab for the treatment of multiple myeloma
- (2014) Philippe Moreau et al. Future Oncology
- A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
- (2014) Caroline S Breton et al. Journal of Hematology & Oncology
- Current treatment landscape for relapsed and/or refractory multiple myeloma
- (2014) Meletios A. Dimopoulos et al. Nature Reviews Clinical Oncology
- Therapeutic Advancements in Multiple Myeloma
- (2014) Alessandro Gozzetti et al. Frontiers in Oncology
- Transformation-Associated Changes in Sphingolipid Metabolism Sensitize Cells to Lysosomal Cell Death Induced by Inhibitors of Acid Sphingomyelinase
- (2013) Nikolaj H.T. Petersen et al. CANCER CELL
- Choosing treatment options for patients with relapsed/refractory multiple myeloma
- (2013) Roberto Castelli et al. Expert Review of Anticancer Therapy
- Lysosomal cell death at a glance
- (2013) S. Aits et al. JOURNAL OF CELL SCIENCE
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- Unknown
- (2013) Antonella Chillemi et al. MOLECULAR MEDICINE
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
- (2012) S. Kumar et al. BLOOD
- Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
- (2012) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
- (2012) D Kim et al. LEUKEMIA
- CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Combating apoptosis and multidrug resistant cancers by targeting lysosomes
- (2010) Line Groth-Pedersen et al. CANCER LETTERS
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
- (2010) Prashant Kapoor et al. MAYO CLINIC PROCEEDINGS
- Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology
- (2010) Thomas Kirkegaard et al. NATURE
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
- (2009) D. Reece et al. BLOOD
- Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton
- (2009) S. Barbier et al. HAEMATOLOGICA
- Cysteine Cathepsins Trigger Caspase-dependent Cell Death through Cleavage of Bid and Antiapoptotic Bcl-2 Homologues
- (2008) Gabriela Droga-Mazovec et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation
- (2008) Sébastien Conus et al. JOURNAL OF EXPERIMENTAL MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started